2010Urology Research and PracticeRequires access

Protective effect of pyrrolidine dithiocarbamate on kidney tissue in streptozotocin-induced diabetic rats

Bekir Aras, Volkan Tuğcu, Gülay Aşık Eren, Bircan Mutlu, Mehmet Uhri, Emin Özbek, Ali İhsan Taşçı

Open publisher page 5 citations

Abstract

Objective: In this study, we investigated protective effects of pyrrolidine dithiocarbamate (PDTC), which is an antioxidant and nuclear factor kappa B (NF-κB) inhibitor, on nephropathy in diabetic rat model. Materials and methods: Twenty-eight Sprague-Dawley rats were allocated into 3 groups. Control group (n=8) received no treatment; diabetes group (n=10) received single intraperitoneal (i.p.) injection of streptozotocin (STZ, 65 mg/kg) to induce experimental diabetes; and PDTC group (n=10) received i.p. 100 μL/day PDTC for a total of 10 weeks following diabetes induction with i.p. STZ injection. At the end of the study kidneys were excised from sacrificed rats, and glomerular and tubular changes were examined under light microscopy. Immunohistochemically, NF-κB (p65) and inducible nitric oxide synthase (iNOS) expression were evaluated in the renal cortex. Results: In diabetes group, immunohistochemical NF-κB expression was higher than control and PDTC groups (p<0.05). In PDTC group, NF-κB expression level was very similar to control group, but less than diabetes group (p<0.05). Immunohistochemical iNOS expression was less in control group. In PDTC group, iNOS expression was more intense than control group (p<0.05), but less than that in diabetes group (p<0.05). Conclusion: PDTC has a protective effect on renal injury secondary to diabetes and can be a treatment option for patients with diabetic nephropathy.

About this research paper

What this paper is about

Objective: In this study, we investigated protective effects of pyrrolidine dithiocarbamate (PDTC), which is an antioxidant and nuclear factor kappa B (NF-κB) inhibitor, on nephropathy in diabetic rat model. Materials and methods: Twenty-eight Sprague-Dawley rats were allocated into 3 groups. Control group (n=8) received no treatment; diabetes group (n=10) received single intraperitoneal (i.p.) injection of streptozotocin (STZ, 65 mg/kg) to induce experimental diabetes; and PDTC group (n=10) received i.p. 100 μL/day PDTC for a total of 10 weeks following diabetes induction with i.p. STZ injection. At the end of the study kidneys were excised from sacrificed rats, and glomerular and tubular changes were examined under light microscopy. Immunohistochemically, NF-κB (p65) and inducible nitric oxide synthase (iNOS) expression were evaluated in the renal cortex. Results: In diabetes group, immunohistochemical NF-κB expression was higher than control and PDTC groups (p<0.05). In PDTC group, NF-κB expression level was very similar to control group, but less than diabetes group (p<0.05). Immunohistochemical iNOS expression was less in control group. In PDTC group, iNOS expression was more intense than control group (p<0.05), but less than that in diabetes group (p<0.05). Conclusion: PDTC has a protective effect on renal injury secondary to diabetes and can be a treatment option for patients with diabetic nephropathy.

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective: In this study, we investigated protective effects of pyrrolidine dithiocarbamate (PDTC), which is an antioxidant and nuclear factor kappa B (NF-κB) inhibitor, on nephropathy in diabetic rat model. Materials and methods: Twenty-eight Sprague-Dawley rats were allocated into 3 groups. Control group (n=8) received no treatment; diabetes group (n=10) received single intraperitoneal (i.p.) injection of streptozotocin (STZ, 65 mg/kg) to induce experimental diabetes; and PDTC group (n=10) received i.p. 100 μL/day PDTC for a total of 10 weeks following diabetes induction with i.p. STZ injection. At the end of the study kidneys were excised from sacrificed rats, and glomerular and tubular changes were examined under light microscopy. Immunohistochemically, NF-κB (p65) and inducible nitric oxide synthase (iNOS) expression were evaluated in the renal cortex. Results: In diabetes group, immunohistochemical NF-κB expression was higher than control and PDTC groups (p<0.05). In PDTC group, NF-κB expression level was very similar to control group, but less than diabetes group (p<0.05). Immunohistochemical iNOS expression was less in control group. In PDTC group, iNOS expression was more intense than control group (p<0.05), but less than that in diabetes group (p<0.05). Conclusion: PDTC has a protective effect on renal injury secondary to diabetes and can be a treatment option for patients with diabetic nephropathy.

Key concepts: Pyrrolidine dithiocarbamate, Streptozotocin, Dithiocarbamate, Kidney, Diabetes mellitus, Pyrrolidine, Internal medicine, Endocrinology

Related papers

Back to paper searchBrowse research topicsOriginal source
Protective effect of pyrrolidine dithiocarbamate on kidney tissue in streptozotocin-induced diabetic rats — Research Paper | ScholarLens